Products - Head and neck cancers | Topic

Showing 18 products

Date | Sort by Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA736)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 October 2021
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 November 2020
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 March 2019
Dinutuximab beta for treating neuroblastoma (TA538)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 August 2018
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 August 2017
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (TA145)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 June 2008
Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
18 October 2023
Head and neck cancer - contusugene ladenovec [ID76]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck ID1355
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy ID940
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with tremelimumab for treating recurrent or metastatic squamous-cell head and neck cancer [ID1558]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lenvatinib with pembrolizumab for untreated PD-L1-positive recurrent or metastatic squamous cell head and neck cancer TS ID 10502
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Head and neck cancers Products

Filter

Product type

Guidance programme
1 selected

Status

New and updated

Showing 18 products

Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA736)

Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)

Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)

Dinutuximab beta for treating neuroblastoma (TA538)

Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)

Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (TA145)

Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]

Head and neck cancer - contusugene ladenovec [ID76]

Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck ID1355

Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy ID940

Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]

Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]

Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429

Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]

Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]

Durvalumab with tremelimumab for treating recurrent or metastatic squamous-cell head and neck cancer [ID1558]

Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]

Lenvatinib with pembrolizumab for untreated PD-L1-positive recurrent or metastatic squamous cell head and neck cancer TS ID 10502

Head and neck cancers Products

Filter

Product type

Guidance programme1 selected

Status

New and updated

Showing 18 products

Guidance programme
1 selected